Drug intelligence / Profile preview

NovoTTF-100A + bevacizumab

Development stage: Unknown
Lead developer: NovoCure
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Transdermal, Intravenous

Overview

NovoTTF-100A (marketed as Optune) is a medical device that delivers tumor treating fields (TTFields)—alternating electric fields designed to disrupt mitosis and induce cell death in rapidly dividing tumor cells. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), inhibiting angiogenesis and reducing tumor blood supply. The combination of NovoTTF-100A and bevacizumab has been investigated for the treatment of recurrent glioblastoma multiforme (GBM). This approach aims to leverage the anti-mitotic effects of TTFields with the antiangiogenic action of bevacizumab to improve progression-free survival and potentially overall survival in patients with recurrent GBM[1][2][3][5].

Brand names: Optune (for NovoTTF-100A)Avastin (for bevacizumab)
Other names: Tumor Treating Fields + bevacizumabTTFields + bevacizumab

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on NovoTTF-100A + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovoTTF-100A + bevacizumab.

Explore the full profile